Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00878930
- Lead Sponsor
- AstraZeneca
- Brief Summary
The objectives of this study is to obtain information of Faslodex use in the treatment of breast cancer in the clinical practice in Argentina.
- Detailed Description
In Argentina, Faslodex is indicated for treating postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen treatment. This study will provide information regarding the acceptability and compliance of Argentina patients to Faslodex and will provide information regarding the efficacy of this treatment in local population.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 500
Inclusion Criteria
- Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-estrogen therapy or disease progression during anti-estrogen treatment, currently receiving Faslodex
- Signature of the informed consent
Exclusion Criteria
- Any contraindication to Faslodex administration
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To collect real life data of efficacy on the use of Faslodex in the Argentine population. monthly To collect real life data of acceptability and compliance on the use of Faslodex in the Argentine population. monthly
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇦🇷Tucuman, Argentina